NCT02303002View on ClinicalTrials.gov

Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines

PHASE2CompletedINTERVENTIONAL
Enrollment

268

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

January 31, 2016

Conditions
Glabellar Frown Lines
Interventions
BIOLOGICAL

Botulinum Toxin Type A

Intramuscular injection (IM)

BIOLOGICAL

Active Comparator botulinum toxin

IM injection

BIOLOGICAL

Placebo Comparator

IM injection

Trial Locations (1)

Unknown

Vancouver

All Listed Sponsors
lead

Revance Therapeutics, Inc.

INDUSTRY

NCT02303002 - Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines | Biotech Hunter | Biotech Hunter